FDA rejects Disc's rare disease drug despite commissioner's voucher Read more
'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments Read more
After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio Read more
This event has passed.
Lunchtime Networking Event
February 4, 2025 @ 11:30 am
Presentations from the Olink team on the value of combining genomic and proteomic data for the best insights into human disease and development of new therapeutics, and more. After, enjoy lunch and networking.
